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Abstract
Background: HIV-infected patients may present an unforeseen clinical worsening after initiating antiretroviral
therapy known as immune reconstitution inflammatory syndrome (IRIS). This syndrome is characterized by a
heightened inflammatory response toward infectious or non-infectious triggers, and it may affect different organs.
Diagnosis of IRIS involving the central nervous system (CNS-IRIS) is challenging due to heterogeneous
manifestations, absence of biomarkers to identify this condition, risk of long-term sequelae and high mortality.
Hence, a deeper knowledge of CNS-IRIS pathogenesis is needed.
Case presentation: A 37-year-old man was diagnosed with AIDS and cerebral toxoplasmosis. Anti-toxoplasma
treatment was initiated immediately, followed by active antiretroviral therapy (HAART) 1 month later. At 2 months of
HAART, he presented with progressive hyposensitivity of the right lower limb associated with brain and dorsal spinal
cord lesions, compatible with paradoxical toxoplasmosis-associated CNS-IRIS, a condition with very few reported cases.
A stereotactic biopsy was planned but was postponed based on its inherent risks. Patient showed clinical improvement
with no requirement of corticosteroid therapy. Routine laboratorial analysis was complemented with longitudinal
evaluation of blood T cell subsets at 0, 1, 2, 3 and 6 months upon HAART initiation. A control group composed by 9
HIV-infected patients from the same hospital but with no IRIS was analysed for comparison. The
CNS-IRIS patient showed lower percentage of memory CD4+ T cells and higher percentage of activated CD4+ T cells at
HAART initiation. The percentage of memory CD4+ T cells drastically increased at 1 month after HAART initiation and
became higher in comparison to the control group until clinical recovery onset; the percentage of memory CD8+ T
cells was consistently lower throughout follow-up. Interestingly, the percentage of regulatory T cells (Treg) on the
CNS-IRIS patient reached a minimum around 1 month before symptoms onset.
Conclusion: Although both stereotactic biopsies and steroid therapy might be of use in CNS-IRIS cases and should be
considered for these patients, they might be unnecessary to achieve clinical improvement as shown in this case.
Immunological characterization of more CNS-IRIS cases is essential to shed some light on the pathogenesis of this
condition.
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Background
Immune reconstitution inflammatory syndrome (IRIS)
occurs in a substantial proportion of patients with hu-
man immunodeficiency virus (HIV) infection during the
first months of highly active antiretroviral therapy
(HAART) [1]. IRIS can be associated to a concomitant
autoimmune disorder, an immune-mediated inflammatory
condition or, most frequently, an infectious disease. In the
last case, IRIS is classified as unmasking or paradoxical,
depending on the infection being subclinical/undiagnosed
or previously diagnosed and treated, respectively [1, 2].
IRIS incidence varies depending on the underlying infec-
tion, reaching up to 40% in HIV-infected patients with
cytomegalovirus retinitis [3]. Low CD4+ T cell count at
HAART onset and high load of an opportunistic pathogen
are the most commonly identified risk factors for IRIS [4].
Although most cases are self-limited, long-term sequelae
and fatal outcomes may occur, particularly when neuro-
logic structures are involved [5].
The immunopathogenesis underlying infection-associated
IRIS is seldom understood and seems to depend on the
underlying pathogen. Although IRIS studies suggested
an involvement of monocytes and NK cells [6, 7],
cells of the adaptive immune system have been considered
the major players. There is evidence that expansion of
pathogen-specific CD4+ T cells accompanies most IRIS
events [8], but differences on T cell responses have not
been consistently identified between patients with or with-
out IRIS [9]. In addition, quantitative and qualitative de-
fects on regulatory T cells (Treg), a specific subset of CD4+
T cells known for its immune suppressive effect, have been
associated with IRIS [10]. Most studies regarding IRIS
immunopathogenesis are based on tuberculosis-associated
IRIS cases, so reports of other types of IRIS to explore the
underlying responsible mechanisms are of great interest.
Encephalitis caused by Toxoplasma gondii is one of
the most common life-threatening central nervous sys-
tem (CNS) infections in patients with acquired immuno-
deficiency syndrome (AIDS) [11]. Infection by T. gondii
is characterized by an asymptomatic acute phase that
may be followed by the dissemination of cysts, mainly to
muscles and brain. CNS toxoplasmosis most often re-
sults from reactivation of the infection, probably due to
the severely depressed T cell-mediated immune response
and imbalanced interactions between intracerebral T
cells, recruited myeloid cells and brain-resident cells, as
suggested by mouse models [12, 13]. CD4+ and CD8+ T
cells have been described as the main players in the
host’s resistance to this infection [14].
Despite the significant incidence of cerebral toxoplas-
mosis, only five paradoxical CNS-IRIS cases associated
to T. gondii have been previously described (Table 1)
[15–18]. Similarly to other IRIS conditions, there is no
consensual treatment for toxoplasmosis-associated IRIS
and prognosis is poor [5]. For these reasons, a better un-
derstanding of the immunopathology is needed to find
biomarkers for early detection and to help developing
targeted therapies leading to a consequent prognosis im-
provement. We report here the sixth case of paradoxical
toxoplasmosis-associated CNS-IRIS and describe for the
first time the evolution of different T cell subsets in the
peripheral blood of the patient.
Methods
Patients
In addition to the T. gondii CNS-IRIS clinical case, a con-
trol group was selected (Table 2) based on the following
inclusion criteria: 1) baseline CD4+ T cell count <100/μL;
2) absence of AIDS-defining conditions at baseline; 3) ab-
sence of IRIS. Participants were all over 18 years old;
chronically infected with HIV-1 (referred as HIV from
now on) and enrolled in the study at the moment of
HAART initiation. The time-points considered for the
present analysis were: 0 (or baseline), 1, 2, 3 and 6 months
after HAART initiation. HAART schemes chosen for each
individual (Table 2) took into consideration: scientific
policy; national and international guidelines [19]; charac-
teristics of each individual; and drug cost. Information re-
garding ethical considerations are available in the “Ethics
approval and consent to participate” section at the end of
this report.
Flow cytometry
Venous blood samples were drawn into Na2-EDTA col-
lecting tubes and processed on the same day. The evalu-
ation of T cell subsets (except Treg) was performed in
200 μL of whole blood upon 15 min incubation with a
combination of antibodies specific for CD3 (clone
OKT3), CD4 (clone RPA-T4), CD8 (RPA-T8), CD45RA
(clone HI100), CD45RO (clone UCHL1), CD69 (clone
FN50) and HLA-DR (clone L243; all from BioLegend, San
Diego, CA, USA). Erythrocytes were lysed upon incubation
with Lysis Buffer (BD Biosciences, San Jose, CA, USA) for
15 min and cells were washed. Treg analysis was performed
in peripheral blood mononuclear cells (PBMCs) isolated
from whole blood by gradient centrifugation. Two million
PBMCs were stained with antibodies specific for CD3
(clone UCHT1), CD4, CD25 (clone BC96), CD31 (clone
WM59) and CD127 (clone AO19D5; all from BioLegend).
Afterwards, cells were washed, fixed, permeabilized and
stained for the intracellular markers FOXP3 (clone
PCH101; eBioscience, San Diego, CA, USA) and Ki67
(clone MOPC-21; BD Biosciences), as described elsewhere
[20]. Samples were acquired on a BD™ LSRII Flow Cytome-
try System using BD FACSDiva software (Franklin Lakes,
NJ, USA). Data were analysed using FlowJo software V.10
(Ashland, OR, USA) accordingly to the gating strategies
represented in Additional file 1: Figures S1 and S2.
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Table 1 Review of the reported clinical cases of paradoxical CNS-IRIS associated to toxoplasmosisa
Toxoplasmosis CNS-IRIS Ref.
Case 1 Female, 30 yo At diagnosis: HIV infection for 6 months,
not on HAART.
Manifestations: Fever, left hemiparesis with
the Babinski sign.
Brain MRI: Ring-enhancing mass in the
right basal nuclei.
Treatment: ATT with trimethoprim–
sulfamethoxazole, corticosteroids, HAART.
Response to treatment: Clinical and
radiographic improvement.
Presentation: Approximately 6 weeks after
toxoplasmosis diagnosis, patient was
readmitted with headaches (for 2 weeks),
imbalance, and left hemiparesis (for 48 h).
Brain MRI: Mass persistence, more vasogenic
edema and new, bilateral but smaller contrast
enhancing lesions. Brain biopsy: Abundant
tachyzoites.
Treatment: Reduction of the corticosteroids
tapering rate.
Outcome: Clinical improvement without complete
resolution (2 months after IRIS diagnosis).
[15]
Case 2 Female, 26 yo At diagnosis: HIV infection for 8 years, not on
HAART. History of cerebral toxoplasmosis
4 years before.
Manifestations: Ataxia, left-sided weakness
and hyperreflexia for 1 month.
Brain CT scan: Scattered calcified lesions
with no perilesional edema or contrast
enhancement.
CSF analysis: Negative PCR for T. gondii.
Brain MRI: Multiple areas of high signal
intensity on fluid-attenuated inversion
recovery (FLAIR) images, some presenting
nodular or ring enhancement.
Treatment: ATT and HAART.
Presentation: After a steady clinical
period of 1 month, progression
of symptoms.
Brain MRI: Enlargement of most of the lesions,
mainly with perilesional high signal intensity
on FLAIR images, as well as stronger contrast
enhancement.
Brain biopsy: Collections of histiocytic giant
multinucleated cells. Marked perivascular
lymphocytic infiltrates with a predominance
of CD8+ T cells. Reactive gliosis. No T.gondii
cysts or tachyzoites.
Treatment: Maintenance of therapeutic measures.
No corticotherapy.
Outcome: Clinical improvement.
[16]
Case 3 Male, 34 yo At diagnosis: HIV infection, non-compliant
with HAART.
Manifestations: Lower extremities weakness
for 6 months, sensory level at L4 and
constipation. Toxoplasma serum IgG level:
Increased. CSF studies: Negative.b
Brain and spine MRI: No contrast-enhanced
brain lesions. Expansive intramedullary
enhancing lesion in spine, at T11 through T12.
Treatment: Laminectomy and surgical spinal
cord decompression, corticosteroids, ATT,
HAART. Pathology of the excised spinal lesion:
T. gondii cysts.
Response to treatment: Clinical improvement.
Presentation: Worsening of weakness 3 weeks
after treatment initiation. Cachexy, dysarthria,
hypotension and areflexia in upper and lower
extremities after one month approximately.
Brain and spine MRI: Two new enhancing
lesions in brain. No new lesions in spine.
CSF studies: All within normal.
Electromyogram/nerve conduction study:
Results consistent with a sensorimotor
neuropathy superimposed on a predominantly
proximal myopathic process.
Muscle biopsy: Necrosis, lymphocytic and
plasma cell infiltrates with abundant T. gondii cysts.c
Outcome: Multiorgan dysfunction and death 2
weeks after the diagnosis of toxoplasmosis myositis.
[17]
Case 4 Male, 35 yo At diagnosis: AIDS previously diagnosed, not
on HAART or prophylaxis.
Manifestations: Left upper extremity weakness
for 3 weeks, associated to fever and
respiratory symptoms for 1 week
(concomitant respiratory infection).
Brain MRI: Two ring-enhancing lesions in the
right precentral and occipital temporal areas.
Treatment: Ceftriaxone and azithromycin,
ATT, HAART.
Presentation: Progression of upper extremity
weakness during the first 2 weeks on HAART.
CSF studies: 6 WBC/mm3 (96% lymphocytes; 4%
monocytes); positive EBV PCR.
Brain MRI: Enlargement of the two prior lesions
and development of a third lesion.
Brain biopsy: Rare T. gondii tachyzoites and
numerous bradyzoites. CD8+ predominant
lymphocytic infiltrates.
Treatment: Corticosteroids. Outcome: Clinical
improvement without complete resolution.
[18]
Case 5 Male, 51 yo At diagnosis: AIDS previously diagnosed, not on
HAART or prophylaxis.
Manifestations: Unsteady gait, left upper extremity
weakness, headaches, weight loss and fever for
2 weeks.
Brain MRI: Multiple ring-enhancing lesions in his
fronto parietal region.
Treatment: ATT, HAART.
Presentation: After an initial improvement, there
was progression of neurological symptoms
around 2 weeks after treatment initiation.
CSF studies: 6 WBC/mm3 (100% lymphocytes);
no malignant cells. Brain MRI: No significant
change. Brain biopsy: Presence of T. gondii. CD8+
predominant lymphocytic infiltrates.
Treatment: Corticosteroids. Outcome: Clinical
improvement.
[18]
Cases are ordered by year of publication. aAll case descriptions reported infection by Toxoplasma gondii, except for case 2 (no species was specified).
bNo specification for T. gondii. cIRIS treatment not available
AIDS acquired immunodeficiency syndrome, ATT anti-toxoplasma therapy (unless otherwise stated, with sulfadiazine, pyrimethamine and folic acid), CNS-IRIS
central nervous system immune reconstitution inflammatory syndrome, CSF cerebrospinal fluid, CT computed tomography, EBV Epstein-Barr virus, HAART highly
active antiretroviral therapy, HIV human immunodeficiency virus, MRI magnetic resonance imaging, PCR polymerase chain reaction, T. gondii Toxoplasma gondii,
WBC white blood cells, yo year-old
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Statistical analysis
Assessment of the distribution of the different variables
was performed by the Shapiro-Wilk Normality Test. Com-
parisons between the control group and the clinical case
were performed by One Sample t-Test or by Wilcoxon
Signed Rank Test, depending on the normal or not nor-
mal distribution of the variables in the control group, re-
spectively. Statistical analyses were performed using the
IBM SPSS v.22 software (Armonk, NY, USA). Differences
were considered statistically significant when p < 0.05 and
graphically marked with * when 0.05 > p > 0.01 or ** when
p ≤ 0.01. Detailed information on the statistical analysis is
supplied in the Additional file 1: Tables S1 and S2.
Case presentation
A 37-year-old man was diagnosed with HIV infection
and cerebral toxoplasmosis. The patient presented head-
ache, psychomotor retardation and left hemiparesis, as-
sociated to advanced immunodeficiency (20 CD4+ T
cells/μL), high plasma HIV load (301,000 copies/mL)
and positive serology for toxoplasmosis. A computed
tomography (CT) scan showed scattered lesions in the
brain parenchyma with perilesional edema, sulcal efface-
ment suggesting mass effect, and some ring contrast en-
hancement (Fig. 1). After initiation of specific anti-
toxoplasma treatment, without corticosteroid therapy, a
clinical and radiologic improvement was observed (Add-
itional file 1: Figure S3). HAART was started 1 month
after HIV diagnosis (drug combination on Table 2) and
toxoplasmosis treatment was maintained for further
1.5 months and then changed to suppressive therapy
(long-term, low-dose therapy to prevent further recur-
rent episodes); primary prophylaxis for other opportun-
istic infections was maintained (Fig. 1).
In a routine medical appointment 3 months after
HAART initiation, the patient presented decreased sen-
sation of the right lower limb that started about 1 month
before. The hyposensitivity started abruptly, with pro-
gressive worsening, extending at that moment to the en-
tire right lower limb and half of the abdomen. The
patient showed neither fever, nor symptoms of the re-
spiratory, digestive or urinary systems. He stated being
compliant to all prescribed therapies (i.e., HAART, ther-
apy for toxoplasmosis and primary prophylaxis for
Mycobacterium avium complex disease). Neurological
examination, mental status and cranial nerves exam
were normal. No papilledema or neck stiffness was
present. Besides a slight sequelar left hemiparesis, an
upper right unilateral sensory level at D-9 was present
with loss of touch sensation and of the ability to feel
pain below this level across the entire right lower limb
and right hemi-abdomen. Proprioception, muscular
force and reflexes were present in the correspondent
area. The patient was immediately admitted to the hos-
pital. A brain CT scan was performed and showed the
previous lesions (a couple revealing worsening with a
slight ring contrast enhancement and perilesional
edema, others revealing improvement) and some new le-
sions (Additional file 1: Figure S4). A magnetic reson-
ance imaging (MRI) of the dorsal spinal cord revealed
myelitis: multiples areas of high signal intensity on the
T2-weighted images, located between D3 and D9, and
probably a posterolateral lesion at D7-D8 (Fig. 1). At this
moment (i.e., 3 months after HAART initiation), the ef-
fect of therapy on the CD4+ T cells and viral load was
already evident; CD4+ T cell count was 128 cells/μL and
the plasma viral load of 121 copies/mL. The cerebro-
spinal fluid (CSF) evaluation showed: 5 cells/μL; 58 mg/
dL protein; 51 mg/dL glucose; negative results for Gram
and acid-fast stains, microbiological cultures, crypto-
coccal antigen, Venereal Disease Research Laboratory
(VDRL) test and polymerase chain reactions (PCR) to
identify other common agents (JC virus, BK virus, cyto-
megalovirus, herpes simplex virus, human herpesviruses
6, varicella-zoster virus, and enterovirus). A CSF PCR
for T. gondii was not performed due to technical limita-
tions. The CSF PCR for Epstein-Barr virus was positive,
but a normal CSF lymphocyte phenotype assay and a
whole-body positron emission tomography (PET) scan
revealed neither hyper-metabolic cerebral nor medullar
Table 2 Demographic and clinical characteristics of the patients
at baseline
IRIS case Control Group
(n = 9)
Gender, Male, % (n) Male 67% (6)
Age at baseline in years, Median
[min; max]
37 44 [28; 48]
HIV transmission mode, % (n)
Intravenous drug user 33% (3)
Men who have sex with
men (MSM)
MSM 22% (2)
Heterosexual 44% (4)
Log10 of HIV viral load at
baseline in copies per mL,
Median [min; max]
5.5 5.4 [4.9; 6.4]
CD4+/μL at baseline, Median
[min; max]
20 25 [8; 97]
HAART regimen components Patient 1:
(TDF + FTC) +
DRVr
Patients 2–7:
(TDF + FTC) + EFV
Patients 8–9:
(ABC + 3TC) +
EFV
2 nucleoside or nucleotide
analogue reverse transcriptase
inhibitors + 3rd drug
(TDF + FTC) +
DRVr
ABC abacavir, DRVr ritonavir boosted darunavir, EFV efavirenz, FTC
emtricitabine, HAART Highly active antiretroviral therapy, HIV human
immunodeficiency virus, TDF tenofovir disoproxil fumarate, 3TC lamivudine
Rb-Silva et al. BMC Infectious Diseases  (2017) 17:66 Page 4 of 11
lesions, which ruled out CNS lymphoma. Serological
HTLV-I/II antibody assay was negative.
The clinical and laboratory information suggested a
potential case of CNS-IRIS. The differential diagnosis
between IRIS and a progression of toxoplasmosis infec-
tion is difficult, but if the last hypothesis was true, most
probably a marked worsening of all the previous lesions
would be present in the brain CT scan. Furthermore, the
patient stated that he had correctly took his anti-
toxoplasma medication.
Because there are no consensual recommendations for
the treatment of toxoplasmosis-associated CNS-IRIS,
anti-toxoplasma therapy with full doses was restarted by
precaution, HAART and prophylaxis for opportunistic
infections were maintained (Fig. 1) and the patient was
kept under close surveillance. Corticosteroids were not
administered.
One month after hospitalization, the clinical status
of the patient was stable and the results of a new
brain and medullar MRI were similar to the previous
one. A stereotactic brain/medulla biopsy was planned,
however it was readily postpone due to its inherent
technical risks as soon as the patient revealed signals
of clinical improvement. A MRI was repeated
4 months later showing a significant improvement of
the brain lesions and a complete resolution of the
medullar lesions. The patient presented fully sensory
recovery about 9 months after HAART onset, only
maintaining the sequelar left hemiparesis. At that
time-point, CD4+ T cell count was 244 cells/μL and
Fig. 1 CNS-IRIS case timeline. On top, a timeline of the clinical evolution shows the temporal relation between toxoplasmosis CNS-IRIS symptoms
onset (yellow arrow); the routine medical appointment followed by hospital admission (pink arrow) and the beginning of the clinical recovery
(green arrow). Blue asterisks mark the five time-points when complete clinical and laboratorial evaluation was performed and blood samples were
collected for flow cytometry analysis. On bottom left, brain CT performed at the initial diagnosis of toxoplamosis. On bottom right, spinal cord
MRI performed after hospital admission. a, b) See Additional file 1: Figure S3 and S4, respectively. c) Suppressive therapy: long-term, low-dose
anti-toxoplasma therapy to prevent further recurrent episodes
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the HIV viral load was <20 copies/mL. The patient
maintained in addition to HAART suppressive treat-
ment for toxoplasmosis for 12 months.
Longitudinal analysis of T cell subsets by flow cytometry
A detailed analysis of T cell subsets evolution was per-
formed in the present CNS-IRIS case. Taking into con-
sideration that this investigation encompasses a single
case of a rare condition, the analysis was complemented
with a group of HIV-infected patients that did not de-
velop IRIS and were followed in the same hospital, all
with <100 CD4+ T cells/μL at baseline and a rapid decline
of the HIV plasma viral load after HAART initiation, simi-
lar to what was observed in the reported case.
 Naïve and memory T cells:
No differences were observed on the absolute
numbers of memory CD4+ or CD8+ T cells
(CD45RA−CD45RO+) between the CNS-IRIS case
and controls at any time-point. The case had a sig-
nificant lower percentage of memory CD4+ T cells
at baseline, but this difference was inverted one
month later (Fig. 2). In both CNS-IRIS case and
controls, there was an increase in the percentage of
memory CD4+ T cells from baseline to 1 month, but
this increase was higher in the CNS-IRIS case (1.4
fold-change) compared to the controls (1.1 mean
fold-change). A higher percentage of memory CD4+
T cells in the CNS-IRIS patient was still present at
symptoms onset and IRIS diagnosis (i.e. 2 and
3 months after HAART initiation).
 T cell activation:
At baseline, there were no differences on the
absolute number of CD4+ or CD8+ T cells
expressing CD69 or HLA-DR between the CNS-IRIS
case and the controls. However, there was a higher
percentage of both CD69+ cells and HLA-DR+ cells
among CD4+ T cells, but not among CD8+ T cells,
in the CNS-IRIS case. The absolute number of
HLA-DR+ CD4+ T cells in the CNS-IRIS case
increased from baseline (when it was similar to the
controls) up to 3 months on HAART (when IRIS
was diagnosed). In contrast, the percentage of
HLA-DR+ cells among CD4+ T cells decreased
from baseline until 2 months on HAART (at IRIS
symptoms onset). After 6 months on HAART, the
absolute number of CD4+ T cells expressing CD69
or HLA-DR was higher in the CNS-IRIS compared
to the controls. This difference was not observed in
CD8+ T cells (Fig. 2).
 Regulatory T cells:
There was no statistically significant difference on
Treg percentage among CD4+ T cells or absolute
number between controls and the clinical case at
baseline (Fig. 3). However, while the mean Treg
percentage continuously decreased after HAART
initiation in the controls, the CNS-IRIS patient
presented first a decrease, reaching a minimum at
1 month of HAART, and then an increase of this
percentage, until 3 months of HAART (when IRIS
was diagnosed, the patient was hospitalized and the
therapy changed). After 6 months on HAART, Treg
percentage was similar between the CNS-IRIS case
and the controls. Regarding Treg subsets, there was
a higher absolute number and percentage of naïve
Treg and recent thymic emigrants Treg in the
CNS-IRIS patient, compared to the controls, at
baseline and 3 months after HAART initiation.
The CNS-IRIS case presented a higher Treg
proliferation rate between 1 and 2 months on
HAART, compared to the controls. This difference
inverted at 3 months on HAART, and was not
present 3 months after (Fig. 3).
Discussion
CNS-IRIS stands of high clinical relevance mainly be-
cause it contributes to the bulk of IRIS mortality [21]
and its prevalence is most probably underestimated
since diagnosis is hampered by the heterogeneous mani-
festations, CNS poor access to clinical investigation, ab-
sence of specific biomarkers and the need to exclude
other conditions. CNS-IRIS diagnosis is presently based
on a multi-parametrical assessment, including: 1) high
pathogen load; 2) positive response to HAART with evi-
dence of controlled HIV replication; 3) short temporal
gap between HAART onset and disease worsening (usu-
ally up to 3 months); 4) inflammatory reaction associ-
ated with the worsening of previous lesions or the
appearance of new lesions; 5) exclusion of differential
diagnosis and; 6) clinical and radiological improvement
without specific empiric therapies. All these criteria were
observed in the case described herein. To better under-
stand the clinical features of paradoxical toxoplasmosis-
associated CNS-IRIS, we summarized the information of
the previously reported 5 cases [15–18] (Table 1) and
compared with the new reported case.
Contrary to the other 5 cases in which HIV infection
was diagnosed before cerebral toxoplasmosis, in the
present CNS-IRIS patient both conditions were diag-
nosed simultaneously. No differences in the immune
pathogenesis or clinical evolution are expected due to
this, since none was under HAART at the moment of
toxoplasmosis diagnosis, except one patient that was
non-compliant to therapy [17]. The neurologic symptoms
of toxoplasmosis were relatively similar between the 6
cases: all patients presented weakness of upper or lower
extremities. Anti-toxoplasma therapy was composed by
sulfadiazine, pyrimethamine and folic acid, except in the
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case described by Tremont-Lukast et al. [15], in which the
patient was treated with trimethoprim–sulfamethoxazole.
Regarding the onset of IRIS symptoms in the previ-
ously described reports, it occurred in the first 3 weeks
on HAART, while in the case described herein, IRIS
symptoms only appeared 2 months after HAART initi-
ation. Still, this period is quite variable from case to case,
typically from a few days to 6 months upon HAART ini-
tiation [1]. All patients performed repeated MRI, and all
but one (our case) had histological studies (brain, in 4
cases; spinal medulla and muscle, in the other). Stereo-
tactic biopsies are very important for diagnosis confirm-
ation and treatment adjustment in HIV-infected patients
[22], but there is a risk of severe complications, such as
intracranial haemorrhage. The use of MRI imaging in as-
sociation with a good clinical judgement and close mon-
itoring avoided an unnecessary and perilous brain or
medullar biopsy in the case here reported.
CSF evaluation was performed after IRIS symptoms
onset in the present CNS-IRIS case and in 3 of the pre-
viously reported cases [17, 18]. Though these analyses
focus on increased levels of anti-toxoplasma IgG or IgM
or the presence of T. gondii DNA, the negativity of these
results does not exclude toxoplasmosis, given the limited
sensitivity of the techniques used.
Therapeutic strategies for IRIS are still controversial
[23], and there is no controlled studies supporting the
use of pharmacologic interventions in CNS-IRIS.
Fig. 2 Evolution of CD4+ and CD8+ T cells and their memory and activated subsets throughout HAART. Absolute numbers of CD4+ T and CD8+
cells and their subsets of memory (CD45RA−CD45RO+) and activated (CD69+ or HLA-DR+) cells are represented on the left graphs, and
percentages, on the right graphs. Gating strategy used to define these populations are depicted in Additional file 1: Figure S1. All comparisons
were performed using One Sample t-Test, except the ones marked with A, in which One-Sample Wilcoxon Signed Rank Test was used.
* represents 0.05 > p > 0.01 and **, p≤ 0.01
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Corticotherapy should be carefully considered in HIV-
infected patients with CNS-IRIS since it increases the
risk of opportunistic infections and may worsen an
undiagnosed condition. Four of the 5 previously re-
ported patients received corticosteroids: although 3 of
these had a favourable evolution [15, 18], the other pa-
tient presented a fatal outcome [17]. There was no
administration of corticotherapy in 2 cases (here and the
one from Cabral et al. [16]) and still patients had a
favourable outcome.
Case reports represent an important study design in ad-
vancing medical scientific knowledge on rare pathological
conditions. While CNS-IRIS immunopathogenesis is still
under active investigation, it seems to mostly depend on
the T cell-mediated response [24, 25]. Therefore, we per-
formed a longitudinal analysis of T cell subsets in the
CNS-IRIS case and compared the results with the ones
from a control group of HIV-infected patients. The differ-
ences need to be addressed cautiously for two main rea-
sons: 1) only one clinical case was studied due to the fact
that this condition is largely unexpected and rare; 2) the
selection criteria of the control group did not exclude
some underlying conditions that might impact on the
assessed parameters. An interesting control group would
be toxoplasma/HIV co-infected individuals who did not
develop IRIS, but no such cases occurred in our cohort
study, in which 85 HIV-infected patients were followed
for 24 months. Notwithstanding, this represents a valuable
characterization of the clinical case that might be relevant
to better understand toxoplasmosis associated CNS-IRIS
immunopathogenesis.
Differences already present before HAART introduc-
tion in HIV-infected patients that develop IRIS, compar-
ing to those patients that do not, may point to an
increased IRIS susceptibility. In this case, the CNS-IRIS
patient presented lower percentages of memory cells
among CD4+ and among CD8+ T cells, and higher levels
of activation of CD4+ T cells, at baseline. Contrary to
our results, the retrospective study by Antonelli et al.
[26] that compared 16 HIV-infected patients with differ-
ent forms of IRIS with 29 HIV-infect patients without
IRIS, showed no differences on baseline T cells populations.
This inconsistency may be explained by the heterogeneity
of IRIS patients included in that retrospective study (tuber-
culosis-IRIS, cryptococcosis-IRIS and others).
In general terms, the expected immune recovery after
HAART initiation implies restoration of the CD4+ T cell
count, which is characterized by two phases: 1) firstly,
recirculation of activated memory T cells that had previ-
ously been sequestered in lymphoid tissues (cell redistri-
bution); 2) secondly (4–6 weeks later or longer in
patients with advanced disease), increase in the naïve
CD4+ T cell counts related to improved thymopoiesis
[27–29]. Accordingly, we observed an increase in the
percentage of memory CD4+ T cells after 1 month of
HAART, in both CNS-IRIS case and controls, but the
Fig. 3 Evolution of regulatory T cells (Treg) throughout HAART. Absolute numbers of total Treg (FOXP3+CD25+CD127−CD4+ T cells), naïve
(CD45RA+) Treg, recent thymic emigrants (RTE; CD45RA+CD31High) Treg and Treg undergoing proliferation (Ki67+) are represented on the left
graphs, and percentage, on the right graphs. Gating strategy used to define these populations is depicted in Additional file 1: Figure S2. All
comparisons were performed using One Sample t-Test, except the ones marked with A, in which One-Sample Wilcoxon Signed Rank Test was
used. * represents 0.05 > p > 0.01 and **, p≤ 0.01
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former showed a higher increase than the latter. On a
report from Antonelli et al. [26], no differences were ob-
served on the absolute number of memory CD4+ T cells
between IRIS and non-IRIS HIV-infected patients,
though a higher proportion of effector memory cells
among CD4+ T cells was reported in IRIS patients com-
pared to patients that did not develop IRIS. Altogether,
this data suggests that IRIS might be associated with an
altered immune recovery, though it would be of much
relevance to assess T cell function to further clarify if
these cells underlie IRIS development.
One hallmark of IRIS pathogenesis, independently of
the clinical presentation and associated pathogen, is an
excessive activation of the immune system [23, 26]. We
studied the expression of two surface activation-
associated molecules on T cells: CD69, the earliest
marker acquired after cell activation, and HLA-DR, a
MHC class II molecule that is over-expressed later [30].
Our data support the hypothesis that higher activation
of CD4+ T cells can be associated with a higher suscepti-
bility to IRIS or be a feature of IRIS pathogenesis, but
further studies are needed. Despite the activation profile
of T cells on the CSF of the IRIS patient was not
assessed, no major alterations would be expected as a
normal cell count was observed. This data is in accord-
ance with previous reports, where normal cell counts
were observed on CSF of 2 patients with toxoplasmosis-
associated CNS-IRIS not withstanding the presence of
an intense inflammatory profile on the brain biopsies of
those patients [31, 32].
Treg are known for their suppressive effect on the im-
mune system [33]. The role of Treg in pathogenesis of
HIV infection is very controversial. On one hand, Treg
may have a beneficial role by downregulating immune
activation and minimizing damage to self-tissues. Several
studies showed that Treg correlate with decreased levels
of T cell activation in HIV-infected patients [34–36], but
at least one study showed a positive correlation between
Treg proportion in blood and CD4+ T cell activation
[37]. On the other hand, Treg may be detrimental by
weakening the host immune response against HIV
[38, 39] and serving as reservoirs for the virus [40]. How-
ever, there is also evidence that Treg directly inhibit HIV
replication in activated T cells [41] and that protective
HIV-specific CD8+ T cells evade Treg cell suppression
[42]. Therefore, it seems that Treg play a dual role in the
progression of HIV infection, as reviewed elsewhere
[10, 43, 44]. There is some evidence that Treg present
quantitative and qualitative alterations in IRIS cases
[26, 45], but there is no consensus about their role in this
condition. In our CNS-IRIS case, there was a decrease,
followed by an increase, of the Treg percentage among
CD4+ T cells. An increased proportion of Treg was
previously observed in patients suffering from other
types of IRIS, including mycobacterial- and crypto-
coccal-related IRIS [45, 46]. While an impaired Treg func-
tion could explain the excessive inflammation that
characterizes IRIS, this has not been convincingly demon-
strated. Unfortunately, no functional tests were performed
to evaluate Treg suppressive activity in our CNS-IRIS case
due to sample scarcity. Further studies on the evolution of
Treg subsets and function in IRIS are required.
Conclusion
Clinicians need to remain aware that HIV-infected pa-
tients with CNS toxoplasmosis are at risk of developing
CNS-IRIS upon HAART initiation. Although this is a
rare condition, it may lead to long-term sequelae and in-
creased mortality, and this report may be useful for
those facing the challenge of a potential CNS-IRIS diagno-
sis. In this clinical context, the use of MRI in association
with clinical and laboratory data can reduce the number
of unnecessary cerebral biopsies; additionally, corticoster-
oid therapy might not be necessary as the patient success-
fully recovered from his condition without it. Though we
observe some alterations on the blood T cell subsets
analysis that could underlie toxoplasmosis CNS-IRIS
pathogenesis, the immunophenotypical characterization of
other toxoplasmosis CNS-IRIS cases, as well as assessment
of T cell function, will be essential to shed some light on
the pathogenesis of this condition. A deeper knowledge on
the mechanisms behind CNS-IRIS will help to define bio-
markers for diagnosis and/or prognosis of this syndrome,
helping clinicians to provide a more effective care.
Additional file
Additional file 1: Supplementary Materials. (PDF 2892 kb)
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